Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.
All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on February 22, 2023, that its Compensation Committee approved the grant of 180,000 restricted stock unit awards (RSUs) to a new employee under the 2019 Inducement Equity Incentive Plan. The RSUs are part of Spero's strategy to attract talent in the biopharmaceutical sector, particularly as the company focuses on developing treatments for rare diseases and multi-drug resistant bacterial infections. The RSUs will vest over four years, starting March 1, 2024, based on continued employment. Spero is known for its investigational therapies, including SPR720 and tebipenem HBr, addressing significant medical needs.
Spero Therapeutics, a clinical-stage biopharmaceutical company, announces participation in two major healthcare conferences. Ankit Mahadevia, CEO, will present at the Cowen 43rd Annual Healthcare Conference on March 7, 2023, and at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023. These events will focus on Spero's development of treatments for rare diseases and multi-drug resistant bacterial infections, including the investigational drugs SPR720 and Tebipenem HBr. Both presentations will be accessible via webcasts, with replays available on Spero's website.
Spero Therapeutics (Nasdaq: SPRO) announced on January 27, 2023, that its Compensation Committee has approved the grant of 16,000 restricted stock unit awards (RSUs) to two new employees under the 2019 Inducement Equity Incentive Plan. This plan grants RSUs to new employees as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments starting February 1, 2024, contingent on the employees' continued employment. Spero Therapeutics specializes in developing treatments for rare diseases and multi-drug resistant bacterial infections.
Spero Therapeutics (Nasdaq: SPRO) announced on December 19, 2022, that its Compensation Committee granted 155,000 restricted stock units (RSUs) to a new employee as part of the Spero Therapeutics 2019 Inducement Equity Incentive Plan. The RSUs, designed to incentivize new hires, will vest in four equal annual installments, starting January 3, 2024, contingent on the employee's ongoing role at Spero. The 2019 Inducement Plan allows for equity awards to individuals not previously employed by Spero, aligning with Nasdaq Rule 5635(c)(4).
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the participation of CEO Ankit Mahadevia in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022. The event will be virtual, with the chat scheduled for November 29 at 8:00 AM ET. A webcast link is provided for access. Spero Therapeutics is focused on developing treatments for rare diseases and multi-drug resistant bacterial infections, with notable product candidates including SPR720, tebipenem HBr, and SPR206.
Spero Therapeutics has entered an exclusive license agreement with GSK for tebipenem HBr, receiving a $66 million upfront payment and a $9 million equity investment. This deal offers potential milestone payments and tiered royalties thereafter. The company has initiated a Phase 2 trial for SPR720, targeting nontuberculous mycobacterial pulmonary disease, with top-line results expected in 1H 2024. Spero reported a Q3 2022 net loss of $11.7 million, a decrease from $22.5 million in the previous year, with cash reserves bolstered by the GSK deal.
Spero Therapeutics announced the closing of a significant licensing agreement with GlaxoSmithKline (GSK) for tebipenem HBr, an investigational oral antibiotic for treating complicated urinary tract infections. Spero will receive a $66 million upfront payment and a $9 million equity investment, with potential future milestone payments up to $525 million, along with tiered royalties on sales. Under the agreement, Spero remains responsible for a follow-up Phase 3 clinical trial, while GSK will manage further development and commercialization.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a conference call on November 14, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and business updates. The call can be accessed via phone or an audio webcast on Spero's website. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Key products include SPR720 for rare pulmonary disease and tebipenem HBr for complicated urinary tract infections, both currently under development and not FDA-approved.
Spero Therapeutics (Nasdaq: SPRO) announced the acceptance of 7 abstracts at IDWeek™ 2022, from October 19-23 in Washington, DC. The presentations will include data on tebipenem HBr and SPR206, focusing on their effectiveness against complicated urinary tract infections (cUTI) and pulmonary infections. Notable studies include clinical outcomes from the Phase 3 ADAPT-PO study and pharmacokinetics of SPR206. Tebipenem HBr is a late-stage oral antibiotic candidate with potential FDA approval for treating cUTI. Spero also highlights collaborations with various health organizations.
Spero Therapeutics, Inc. (Nasdaq: SPRO) is hosting a virtual R&D event on October 6, 2022, at 11:30 a.m. ET. Key opinion leader Kevin L. Winthrop, MD, MPH, will discuss the treatment landscape for non-tuberculous mycobacteria (NTM) pulmonary disease, alongside presentations from Spero's management about SPR720, a potential novel oral therapy for NTM infections. A live Q&A session will follow the presentations. Interested participants can register for the event here.